Why the study?
What is the evidence supporting current guidelines for the pharmacologic management of venous thromboembolic disease in pregnancy?
What is the evidence supporting current guidelines for the pharmacologic management of venous thromboembolic disease in pregnancy?
This review highlights the evidence supporting current guidelines for managing venous thromboembolism in pregnancy, emphasizing the need for more randomized trials.
Answers are grounded in this paper and cite their sources.
Guidelines for pregnancy VTE remain appropriate; leaves open need for RCTs to confirm optimal regimens.
Pulmonary embolism is a major, but potentially preventable, cause of maternal mortality in North America and Europe. Because venous thromboembolism is an infrequent cause of maternal morbidity, there are few randomized clinical trials to guide clinical decision-making with respect to treatment, prevention, and evaluation of innovative management modalities such as low molecular weight heparin. This article focuses on the evidence supporting the current guidelines for the pharmacologic management of venous thromboembolic disease in pregnancy.
No takes yet. Share an insight, caveat, or question.
Karen Valentine (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: